Coagulation abnormality as a complication of L-asparaginase therapy in childhood lymphoblastic leukemia
Keywords:
L-asparaginase, childhood ALL, coagulation, bleeding
Abstract
Background Bleeding, one of the most common symptoms ofacute leukemia in untreated patients, is mostly due to thrombocy-
topenia as a result of myeloinvasion by leukemic cells. Neverthe-
less, a further contributory factor for the additional hemorrhagic
complication during intensive chemotherapy is the myelosuppressive
effect of most active drugs. L-asparaginase, one of the cytostatics
used during remission induction therapy for childhood of acute
lymphoblastic leukemia (ALL), is widely reported to impair the he-
mostatic system.
Objective To determine the influence of shorter courses of L-as-
paraginase (L-Ase) on some of the hemostatic parameters in the
treatment of childhood ALL.
Methods A prospective analytical study was carried out in the
Department of Child Health, Cipto Mangunkusumo Hospital Jakarta
from July 1, 1999 to June 30, 2001 on newly diagnosed ALL pa-
tients with normal liver function tests treated according to our na-
tional ALL protocol which one of its composition contained 6 in-
stead of 9 injections of L-asparaginase.
Results All of 30 children with ALL included in the study, experi-
enced prolongation of prothrombin time (PT), activated partial
thromboplastin time (aPTT), and decreased fibrinogen concentra-
tion, markedly during the administration of L-asparaginase. How-
ever, none of the patients had additional hemorrhage or evidence
of disseminated intravascular coagulation (DIC).
Conclusion The use of shorter courses of L-asparaginase, 6 in-
jections, in the remission induction chemotherapy of childhood ALL
in our department may reduce the blood clotting factors without
further hemorrhage complication or evidence of DIC
References
1. Mohri H. Acquired von Willebrand disease and stor-
age pool disease in chronic myelocytic leukemia. Am J
Hematol 1986;22:391-401.
2. Homans AC, Rybak ME, Baglini RL, Tiarks C, Steiner
ME, Forman EN. Effect of L-asparaginase administra-
tion on coagulation and platelet function in children
with leukemia. J Clin Oncol 1987;5:811-7.
3. Ramsay NK, Coccia PF, Krivit W, Nesbit ME, Edson JR.
The effect of L-asparaginase on plasma coagulation fac-
tors in acute lymphoblastic leukemia. Cancer 1977;40:
1398-401.
4. Sills RH, Nelson DA, Stockman JA. L-asparaginase-in-
duced coagulopathy during therapy of acute lympho-
blastic leukemia. Med Pediatr Oncol 1978;4:311-3.
5. Gralnick HR, Henderson E. Hypofibrinogenemia and
coagulation factor deficiencies with L-asparaginase treat-
ment. Cancer 1971;27:1313-20.
6. Priest JR, Ramsay NK, Latchaw RE, Lockman LA,
Hasegawa DK, Coates TD, et al. Thrombotic and hem-
orrhagic strokes complicating early therapy for childhood
acute lymphoblastic leukemia. Cancer 1980;46:1548-54.
7. Priest JR,Ramsay NK, Bennett AJ, Krivit W, Edson JR.
The effect of L-asparaginase on antithrombin, plasmi-
nogen, and plasma coagulation during therapy for acute
lymphoblastic leukemia. J Pediatr 1982;100:984-9.
8. Barrowcliffe TW, Kirkwood TB, Rizza CR. Alumunium
hydroxide adsorption and factor VIII clotting assays. Lan-
cet 1980;1:820.
9. Gralnick HR, Abrell E. Studies of the procoagulant
and fibrinolytic activity of promyelocytes in acute
promyelocitic leukemia. Br J Hematol 1973;24:89-99.
10. Gralnick HR, Sultan C. Annotation: Acute promyelocytic
leukemia, haemorrhagic manifestation and morphologic
criteria. Br J Hematol 1975;29:373-6.
11. Anderson N, Lokich JJ, Tullis JL. L-asparaginase effect
on antithrombin-III levels. Med Pediatr Oncol
1979;7:335-40.
12. Buchanan GR, Holtkamp CA. Reduced antithrombin
III levels during L-asparaginase therapy. Med Pediatr
Oncol 1980;8:7-14.
13. Vellenga E, Mulder NH, Nieweg HO. Antithrombin III
deficiency during asparaginase therapy. Lancet
1980;1:649-50.
14. Barbui T, Finazzi G, Falanga A. The management of
bleeding and thrombosis in leukemia. In: Henderson ES,
Lister TA, Greaves MF, editors. Leukemia: 6th ed. Phila-
delphia: Saunders, 1996. p. 291-300.
15. Pui CH, Jackson CW, Chesney CM, Lyles SA, Bowman
WP, Abrowictch M, et al. Sequential changes in platelet
function and coagulation in leukemic children treated
with L-asparaginase, prednisone, and vincristine. J Clin
Oncol 1983;1:380-5.
16. Vellenga E, Kluft C, Mulder NH, Wijngaards G,
Nieweg HO. The influence of L-asparaginase therapy
on the fibrinolytic system. Br J Haematol 1984;57:
247-54.
17. Gatot D, Windiastuti E, Abdulsalam M, Munthe BG.
Treatment of Childhood Acute Lymphoblastic Leu-
kemia. The Jakarta Experience. Presented at the 17 th
Asia Pacific Cancer Conference, Bali; 2003 Octo-
ber 8-11.
18. Jaffe N, Traggis L, Das WC, Das L, Moloney, Hann HW,
Kim BS, et al. L-asparaginase in the treatment of neo-
plastic diseases in children. Cancer Res 1971;31:942-8.
19. Land VJ, Sutow WW, Fernbach DJ, Lane DM, Williams
TE. Toxicity of L-asparaginase in children in advanced
leukemia. Cancer 1972;30:339-43.
20. Pui CH, Chesney CM, Bergum PW, Jackson CW,
Rappaport SI. Lack of pathogenic role of protein C and
S in thrombosis associated with asparaginase-pred-
nisone-vincristine therapy for leukemia. Br J Haematol
1986;64:283-90.
21. Saito M, Asakura H, Jokaji H, Uotani C, Kumabashiri I,
Ito K, et al. Changes in hemostatic and fibrinolytic pro-
teins in patients receiving L-asparaginase therapy. Am J
Hematol 1989;32:20-3.
22. Al-Mondhiry H. Hypofibrinogenemia associated with
vincristine and prednisone therapy in lymphoblastic
leukemia. Cancer 1975;35:144-7.
23. Betticole RE, Himelstein ES, Oettgen HF, Clifford GO.
Hypofibrinogenemia due to L-asparaginase: Studies on
fibrinogen survival using autologous I-fibrinogen. Blood
1970;35:195-200.
age pool disease in chronic myelocytic leukemia. Am J
Hematol 1986;22:391-401.
2. Homans AC, Rybak ME, Baglini RL, Tiarks C, Steiner
ME, Forman EN. Effect of L-asparaginase administra-
tion on coagulation and platelet function in children
with leukemia. J Clin Oncol 1987;5:811-7.
3. Ramsay NK, Coccia PF, Krivit W, Nesbit ME, Edson JR.
The effect of L-asparaginase on plasma coagulation fac-
tors in acute lymphoblastic leukemia. Cancer 1977;40:
1398-401.
4. Sills RH, Nelson DA, Stockman JA. L-asparaginase-in-
duced coagulopathy during therapy of acute lympho-
blastic leukemia. Med Pediatr Oncol 1978;4:311-3.
5. Gralnick HR, Henderson E. Hypofibrinogenemia and
coagulation factor deficiencies with L-asparaginase treat-
ment. Cancer 1971;27:1313-20.
6. Priest JR, Ramsay NK, Latchaw RE, Lockman LA,
Hasegawa DK, Coates TD, et al. Thrombotic and hem-
orrhagic strokes complicating early therapy for childhood
acute lymphoblastic leukemia. Cancer 1980;46:1548-54.
7. Priest JR,Ramsay NK, Bennett AJ, Krivit W, Edson JR.
The effect of L-asparaginase on antithrombin, plasmi-
nogen, and plasma coagulation during therapy for acute
lymphoblastic leukemia. J Pediatr 1982;100:984-9.
8. Barrowcliffe TW, Kirkwood TB, Rizza CR. Alumunium
hydroxide adsorption and factor VIII clotting assays. Lan-
cet 1980;1:820.
9. Gralnick HR, Abrell E. Studies of the procoagulant
and fibrinolytic activity of promyelocytes in acute
promyelocitic leukemia. Br J Hematol 1973;24:89-99.
10. Gralnick HR, Sultan C. Annotation: Acute promyelocytic
leukemia, haemorrhagic manifestation and morphologic
criteria. Br J Hematol 1975;29:373-6.
11. Anderson N, Lokich JJ, Tullis JL. L-asparaginase effect
on antithrombin-III levels. Med Pediatr Oncol
1979;7:335-40.
12. Buchanan GR, Holtkamp CA. Reduced antithrombin
III levels during L-asparaginase therapy. Med Pediatr
Oncol 1980;8:7-14.
13. Vellenga E, Mulder NH, Nieweg HO. Antithrombin III
deficiency during asparaginase therapy. Lancet
1980;1:649-50.
14. Barbui T, Finazzi G, Falanga A. The management of
bleeding and thrombosis in leukemia. In: Henderson ES,
Lister TA, Greaves MF, editors. Leukemia: 6th ed. Phila-
delphia: Saunders, 1996. p. 291-300.
15. Pui CH, Jackson CW, Chesney CM, Lyles SA, Bowman
WP, Abrowictch M, et al. Sequential changes in platelet
function and coagulation in leukemic children treated
with L-asparaginase, prednisone, and vincristine. J Clin
Oncol 1983;1:380-5.
16. Vellenga E, Kluft C, Mulder NH, Wijngaards G,
Nieweg HO. The influence of L-asparaginase therapy
on the fibrinolytic system. Br J Haematol 1984;57:
247-54.
17. Gatot D, Windiastuti E, Abdulsalam M, Munthe BG.
Treatment of Childhood Acute Lymphoblastic Leu-
kemia. The Jakarta Experience. Presented at the 17 th
Asia Pacific Cancer Conference, Bali; 2003 Octo-
ber 8-11.
18. Jaffe N, Traggis L, Das WC, Das L, Moloney, Hann HW,
Kim BS, et al. L-asparaginase in the treatment of neo-
plastic diseases in children. Cancer Res 1971;31:942-8.
19. Land VJ, Sutow WW, Fernbach DJ, Lane DM, Williams
TE. Toxicity of L-asparaginase in children in advanced
leukemia. Cancer 1972;30:339-43.
20. Pui CH, Chesney CM, Bergum PW, Jackson CW,
Rappaport SI. Lack of pathogenic role of protein C and
S in thrombosis associated with asparaginase-pred-
nisone-vincristine therapy for leukemia. Br J Haematol
1986;64:283-90.
21. Saito M, Asakura H, Jokaji H, Uotani C, Kumabashiri I,
Ito K, et al. Changes in hemostatic and fibrinolytic pro-
teins in patients receiving L-asparaginase therapy. Am J
Hematol 1989;32:20-3.
22. Al-Mondhiry H. Hypofibrinogenemia associated with
vincristine and prednisone therapy in lymphoblastic
leukemia. Cancer 1975;35:144-7.
23. Betticole RE, Himelstein ES, Oettgen HF, Clifford GO.
Hypofibrinogenemia due to L-asparaginase: Studies on
fibrinogen survival using autologous I-fibrinogen. Blood
1970;35:195-200.
Published
2016-10-18
How to Cite
1.
Gatot D, Pringgardini K, Suradi R. Coagulation abnormality as a complication of L-asparaginase therapy in childhood lymphoblastic leukemia. PI [Internet]. 18Oct.2016 [cited 13Nov.2024];46(1):46-0. Available from: https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/854
Section
Articles
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Received 2016-10-10
Accepted 2016-10-10
Published 2016-10-18
Accepted 2016-10-10
Published 2016-10-18
